IDEAYA Biosciences Inc banner

Intrinsic Value

The intrinsic value of IDEAYA Biosciences Inc (30J) under the Base Case is 19.77 EUR per share. Compared with the current market price of 23.54 EUR, the stock appears Overvalued by 16% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

30J Intrinsic Value
€19.77
Overvaluation 16%
Intrinsic Value
Price €23.54

30J is cheaper than usual. Still overvalued, but less so than on 80% of days in the past 5 years.

Alert me when 30J is below its intrinsic value
Today €15.82 · 32.8% below the current price
Alternatives to 30J

Fundamental Analysis

What IDEAYA Biosciences Does

Biotechnology Health Care

IDEAYA Biosciences is a biotechnology company that develops cancer drugs aimed at tumors with specific genetic weaknesses. Its work focuses on precision oncology, especially small-molecule medicines designed to block the pathways cancer cells depend on while sparing healthier cells. The company’s main assets are its drug candidates and the science behind matching the right drug to the right tumor type.

Headquarters
United States of America US
Employees
145
IPO date
May 23, 2019
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

IDEAYA Biosciences insiders made their first purchases in five years

Insider trading · Last trade on Oct 6, 2026

Sold $1.3m 2 insiders
Bought $1.6m 1 insider
Trades by date
Open insider trading

Past 12 months

Continue 30J Research

Decided on IDEAYA Biosciences? Get an email when 30J reaches the price you’d buy at. Free with an account.

Other IDEAYA Biosciences listings

What is the Intrinsic Value of one 30J stock?

The intrinsic value for IDEAYA Biosciences Inc (30J) under the Base Case is 19.77 EUR.

Is 30J stock undervalued or overvalued?

Compared with the current market price of 23.54 EUR, the stock appears Overvalued by 16% .

How reliable are our estimates? See how past valuations played out
Back to Top